All News
Filter News
Found 331 articles
-
Genentech Provides an Update on the Phase III COVACTA Trial of Actemra in Hospitalized Patients With Severe COVID-19 Associated Pneumonia
7/29/2020
COVACTA trial did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia or the key secondary endpoint of reduced patient mortality
-
BioSpace Movers & Shakers, July 24
7/24/2020
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers. -
Adverum Biotechnologies Announces Appointment of Thomas Kochy as Vice President, Commercial and Program Strategy
7/21/2020
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Thomas Kochy joined the company as vice president, commercial and program strategy. In this newly created position, Mr. Kochy will be responsible for leading commercial planning, product strategy, and program management. This position will report into Adverum’s president, L
-
Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly
7/15/2020
Piclidenoson to be evaluated for the treatment of COVID-19 infected patients with moderate symptoms
-
Tiziana Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19
6/29/2020
This proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir® (Roche) to lungs could potentially be a transformational therapy for developing a rapid treatment for COVID-19
-
In an open letter from the company’s chairman and chief executive officer, Daniel O’Day reported that the U.S. Food and Drug Administration (FDA) had given the company approval to begin clinical trials of an inhaled version of the drug.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.
-
Dexamethasone Reduces Deaths in Hospitalized COVID-19 Patients Needing Oxygen, Study Shows
6/16/2020
Low doses of a long-used steroid known as dexamethasone could be the solution to improving the chances of patients who become seriously ill from COVID-19 infection and require some kind of breathing assistance. -
Eli Lilly will assess its JAK1/JAK2 inhibitor Olumiant (baricitinib) as a potential treatment for COVID-19 in a Phase III study.
-
Instead of detecting the virus, this device can help determine who might be at risk for intubation and mechanical ventilation.
-
Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVID-19
6/4/2020
Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the submission to an international medical journal the results of pre-clinical and clinical evaluation of QuadraMune™ in 32 healthy
-
Clinical Catch-Up: May 25-29
6/1/2020
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look. -
“As more information about COVID-19 pneumonia becomes available in these unprecedented times, it is more important than ever to work together to fight this disease,” said Levi Garraway, Roche’s chief medical officer and head of Global Product Development.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
-
Genentech Initiates Phase III Clinical Trial of Actemra Plus Remdesivir in Hospitalized Patients With Severe COVID-19 Pneumonia
5/28/2020
Genentech is also close to completing enrollment of a global randomized, double-blind, placebo-controlled Phase III clinical trial of Actemra in hospitalized patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer
-
Since COVID-19 began its sweep across the United States, data has shown the disease caused by the novel coronavirus has disproportionately impacted racial and ethnic minority groups across the country.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 28, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 27, 2020.